Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Sell
43
AZN Quote, Financials, Valuation and Earnings
Last price:
$68.76
Seasonality move
:
1.87%
Day range:
$69.85 - $70.69
52-week range:
$61.24 - $87.68
Dividend yield:
2.21%
P/E ratio:
28.14x
P/S ratio:
3.98x
P/B ratio:
5.29x
Volume:
3.5M
Avg. volume:
3.9M
1-year change:
-10.83%
Market cap:
$217.3B
Revenue:
$54.1B
EPS (TTM):
$2.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$14.1B | $1.10 | 8.83% | 84.16% | $85.27 |
|
AMGN
Amgen
|
$8.9B | $5.26 | 5.12% | 3.03% | $313.56 |
|
GSK
GSK PLC
|
$10.6B | $1.14 | 5.94% | 60.08% | $41.72 |
|
MRNA
Moderna
|
$114.4M | -$3.02 | -49.84% | -11.55% | $47.59 |
|
REGN
Regeneron Pharmaceuticals
|
$3.3B | $8.49 | -7.35% | -30.58% | $728.55 |
|
SMMT
Summit Therapeutics
|
-- | -$0.09 | -- | -28.96% | $34.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$70.08 | $85.27 | $217.3B | 28.14x | $1.05 | 2.21% | 3.98x |
|
AMGN
Amgen
|
$299.02 | $313.56 | $160.8B | 27.28x | $2.38 | 3.1% | 4.74x |
|
GSK
GSK PLC
|
$38.28 | $41.72 | $77.8B | 19.85x | $0.43 | 4.18% | 1.97x |
|
MRNA
Moderna
|
$32.06 | $47.59 | $12.4B | -- | $0.00 | 0% | 3.97x |
|
REGN
Regeneron Pharmaceuticals
|
$547.93 | $728.55 | $59.2B | 13.95x | $0.88 | 0.32% | 4.44x |
|
SMMT
Summit Therapeutics
|
$28.27 | $34.52 | $21B | -- | $0.00 | 0% | 21,515.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
42.02% | 0.141 | 13.05% | 0.69x |
|
AMGN
Amgen
|
90.24% | -0.268 | 34.26% | 0.74x |
|
GSK
GSK PLC
|
56.56% | -0.254 | 30.39% | 0.58x |
|
MRNA
Moderna
|
-- | -0.100 | -- | 3.92x |
|
REGN
Regeneron Pharmaceuticals
|
6.33% | 0.047 | 2.89% | 3.90x |
|
SMMT
Summit Therapeutics
|
-- | 0.751 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.3B | $3.7B | 10.93% | 19.55% | 27.61% | $2.7B |
|
AMGN
Amgen
|
$5.2B | $1.2B | 8.85% | 97.08% | 33.08% | $980M |
|
GSK
GSK PLC
|
$7B | $2.8B | 10.19% | 23.08% | 30.2% | $877.6M |
|
MRNA
Moderna
|
$17M | -$1.1B | -29.23% | -29.23% | -900% | -$1.2B |
|
REGN
Regeneron Pharmaceuticals
|
$2.6B | $591.7M | 14.69% | 15.7% | 30.17% | $773.6M |
|
SMMT
Summit Therapeutics
|
-- | -$66.9M | -- | -- | -- | -$61.6M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.23%. AstraZeneca PLC's return on equity of 19.55% beat Amgen's return on equity of 97.08%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B AMGNAmgen63.58% $3.20 $63.6B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $85.27, signalling upside risk potential of 21.67%. On the other hand Amgen has an analysts' consensus of $313.56 which suggests that it could grow by 4.86%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 AMGNAmgen12 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.369, which suggesting that the stock is 63.141% less volatile than S&P 500. In comparison Amgen has a beta of 0.491, suggesting its less volatile than the S&P 500 by 50.876%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. Amgen offers a yield of 3.1% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.1B. AstraZeneca PLC's net income of $2.9B is higher than Amgen's net income of $1.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while Amgen's PE ratio is 27.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 4.74x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B AMGNAmgen4.74x 27.28x $8.1B $1.7B
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.61%. AstraZeneca PLC's return on equity of 19.55% beat GSK PLC's return on equity of 23.08%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B GSKGSK PLC74.23% $0.99 $41.5B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $85.27, signalling upside risk potential of 21.67%. On the other hand GSK PLC has an analysts' consensus of $41.72 which suggests that it could grow by 8.98%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 GSKGSK PLC1 5 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.369, which suggesting that the stock is 63.141% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.514, suggesting its less volatile than the S&P 500 by 48.644%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. GSK PLC offers a yield of 4.18% to investors and pays a quarterly dividend of $0.43 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $9.5B. AstraZeneca PLC's net income of $2.9B is higher than GSK PLC's net income of $2B. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while GSK PLC's PE ratio is 19.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 1.97x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B GSKGSK PLC1.97x 19.85x $9.5B $2B
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -907.48%. AstraZeneca PLC's return on equity of 19.55% beat Moderna's return on equity of -29.23%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B MRNAModerna15.89% -$2.52 $10.1B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of $85.27, signalling upside risk potential of 21.67%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 MRNAModerna4 17 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.369, which suggesting that the stock is 63.141% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Moderna quarterly revenues of $107M. AstraZeneca PLC's net income of $2.9B is higher than Moderna's net income of -$971M. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B MRNAModerna3.97x -- $107M -$971M
-
Which has Higher Returns AZN or REGN?
Regeneron Pharmaceuticals has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 26.7%. AstraZeneca PLC's return on equity of 19.55% beat Regeneron Pharmaceuticals's return on equity of 15.7%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B REGNRegeneron Pharmaceuticals84.67% $7.27 $31.4B -
What do Analysts Say About AZN or REGN?
AstraZeneca PLC has a consensus price target of $85.27, signalling upside risk potential of 21.67%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Regeneron Pharmaceuticals has higher upside potential than AstraZeneca PLC, analysts believe Regeneron Pharmaceuticals is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 REGNRegeneron Pharmaceuticals14 7 0 -
Is AZN or REGN More Risky?
AstraZeneca PLC has a beta of 0.369, which suggesting that the stock is 63.141% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.
-
Which is a Better Dividend Stock AZN or REGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or REGN?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. AstraZeneca PLC's net income of $2.9B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B REGNRegeneron Pharmaceuticals4.44x 13.95x $3B $808.7M
-
Which has Higher Returns AZN or SMMT?
Summit Therapeutics has a net margin of 21.46% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 19.55% beat Summit Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B SMMTSummit Therapeutics-- -$0.09 -- -
What do Analysts Say About AZN or SMMT?
AstraZeneca PLC has a consensus price target of $85.27, signalling upside risk potential of 21.67%. On the other hand Summit Therapeutics has an analysts' consensus of $34.52 which suggests that it could grow by 22.09%. Given that Summit Therapeutics has higher upside potential than AstraZeneca PLC, analysts believe Summit Therapeutics is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 SMMTSummit Therapeutics8 0 0 -
Is AZN or SMMT More Risky?
AstraZeneca PLC has a beta of 0.369, which suggesting that the stock is 63.141% less volatile than S&P 500. In comparison Summit Therapeutics has a beta of -1.012, suggesting its less volatile than the S&P 500 by 201.24%.
-
Which is a Better Dividend Stock AZN or SMMT?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. Summit Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Summit Therapeutics pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or SMMT?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Summit Therapeutics quarterly revenues of --. AstraZeneca PLC's net income of $2.9B is higher than Summit Therapeutics's net income of -$62.9M. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while Summit Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 21,515.21x for Summit Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B SMMTSummit Therapeutics21,515.21x -- -- -$62.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 8.72% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 0.47% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 203% over the past day.
